PDF
ePub
Citation
Print
Abstract
Peptic ulcer disease is one of the most commonly encountered diseases in gastroenterology clinics. After the discovery of Helicobacter pylori by Warren and Marshall, it has been identified as the most important cause of peptic ulcer. Eradication of H. pylori markedly reduces the post-treatment recurrence rate of peptic ulcer. However, as human populations age, the incidence of cardiovascular and musculoskeletal diseases increases and consequent use of aspirin and non-steroidal anti-inflammatory drugs increases. Thus causes and presenting patterns of peptic ulcer have changed. In this review, I describe new diagnostic and therapeutic strategies for peptic ulcer disease and explore future perspectives.
References
1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1:1311–1315.
2. Tan HJ, Goh KL. Changing epidemiology of Helicobacter pylori in Asia. J Dig Dis. 2008; 9:186–189.
3. Chung CS, Chiang TH, Lee YC. A systematic approach for the diagnosis and treatment of idiopathic peptic ulcers. Korean J Intern Med. 2015; 30:559–570.
4. Sugano K, Tack J, Kuipers EJ, et al. faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015; 64:1353–1367.
5. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother. 1996; 40:477–480.
6. Kim JS, Park SM, Kim BW. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and metaanalysis. J Gastroenterol Hepatol. 2015; 30:1338–1345.
7. Lu C, Sang J, He H, et al. Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a metaanalysis. Sci Rep. 2016; 6:23522.
8. Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a metaanalysis. PLoS One. 2014; 9:e111030.
9. Takeuchi H, Trang VT, Morimoto N, Nishida Y, Matsumura Y, Sugiura T. Natural products and food components with anti-Helicobacter pylori activities. World J Gastroenterol. 2014; 20:8971–8978.
10. Yamamoto O, Okada Y, Okabe S. Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats. Dig Dis Sci. 1984; 29:394–401.
11. Sikiric P, Rotkvic I, Mise S, et al. Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine. Dig Dis Sci. 1991; 36:905–910.
12. Nishikawa K, Amagase K, Takeuchi K. Effect of dopamine on the healing of acetic acid-induced gastric ulcers in rats. Inflammo-pharmacology. 2007; 15:209–213.
13. Konturek JW. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori. J Physiol Pharmacol. 1994; 45(4 Suppl 1):3–66.
14. Milani S, Calabrò A. Role of growth factors and their receptors in gastric ulcer healing. Microsc Res Tech. 2001; 53:360–371.
15. Deng X, Szabo S, Khomenko T, Jadus MR, Yoshida M. Gene therapy with adenoviral plasmids or naked DNA of vascular endothelial growth factor and platelet-derived growth factor accelerates healing of duodenal ulcer in rats. J Pharmacol Exp Ther. 2004; 311:982–988.
16. He P, Zhou R, Hu G, et al. Curcumin-induced histone acetylation inhibition improves stress-induced gastric ulcer disease in rats. Mol Med Rep. 2015; 11:1911–1916.
XML Download